Ms. Macfarlane joined ForSight Labs as President and CEO in March 2007. Over the past ten years, ForSight has started six VISION companies focused on breakthrough therapies in ophthalmology, which have collectively raised over $150M — including Transcend Medical, Inc. (acquired by ALCON), ForSight Newco II, Inc. (acquired by QLT), NexisVision, Inc. (licensed), Forsight VISION4, Inc. (acquired by Roche) and ForSight VISION5, Inc. (acquired by ALLERGAN). ForSight VISION6, Inc. is an ongoing development stage company operating under a strategic partnership. Ms. Macfarlane brings over 20 years of experience in early stage company creation in both corporate and incubator settings to ForSight.